215 related articles for article (PubMed ID: 25518923)
1. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines.
Kim Y; Han D; Min H; Jin J; Yi EC; Kim Y
Mol Cells; 2014 Dec; 37(12):888-98. PubMed ID: 25518923
[TBL] [Abstract][Full Text] [Related]
2. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
3. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
5. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
8. S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.
Li T; Ren T; Huang C; Li Y; Yang P; Che G; Luo L; Chen Y; Peng S; Lin Y; Zeng L
Biochem Pharmacol; 2021 Jul; 189():114396. PubMed ID: 33359364
[TBL] [Abstract][Full Text] [Related]
9. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
11. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
12. Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Kuo YC; Kou HW; Hsu CP; Lo CH; Hwang TL
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108495
[TBL] [Abstract][Full Text] [Related]
13. Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor.
Nam S; Khawar IA; Park JK; Chang S; Kuh HJ
Biochem Biophys Res Commun; 2019 Jul; 515(1):183-189. PubMed ID: 31133378
[TBL] [Abstract][Full Text] [Related]
14. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance.
Ina S; Hirono S; Noda T; Yamaue H
Pancreas; 2010 May; 39(4):473-85. PubMed ID: 19959962
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
16. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma.
Leung L; Radulovich N; Zhu CQ; Organ S; Bandarchi B; Pintilie M; To C; Panchal D; Tsao MS
PLoS One; 2012; 7(10):e46677. PubMed ID: 23056397
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Meng Q; Shi S; Liang C; Liang D; Hua J; Zhang B; Xu J; Yu X
Oncogene; 2018 Nov; 37(44):5843-5857. PubMed ID: 29980787
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.
Quint K; Tonigold M; Di Fazio P; Montalbano R; Lingelbach S; Rückert F; Alinger B; Ocker M; Neureiter D
Int J Oncol; 2012 Dec; 41(6):2093-102. PubMed ID: 23026911
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]